Californian rare disease company Ultragenyx Pharmaceutical (Nasdaq: RARE) has received a positive reimbursement decision from the UK’s health technology assesso 5 January 2024
Swedish drugmaker Calliditas Therapeutics has received full US Food and Drug Administration approval for Tarpeyo (budesonide), upgrading a previous nod under th 21 December 2023
The rare disease unit of Italian drugmaker Chiesi has secured US approval for Filsuvez (birch triterpenes), a new treatment for people with junctional epidermol 20 December 2023
Midsize Japanese drugmaker Otsuka Pharmaceuticals has entered into a strategic agreement with Ionis Pharmaceuticals (Nasdaq: IONS) related to its candidate doni 19 December 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.